Skip to main content

Day: August 4, 2020

Warner Music Group Corp. Reports Results For Fiscal Third Quarter Ended June 30, 2020

Digital revenue grew 11.1% or 13.4% in constant currencyTotal revenue was down 4.5% or 3.1% in constant currencyNet loss was $519 million versus net income of $14 million in the prior-year quarterOIBDA was a loss of $371 million versus income of $124 million in the prior-year quarterAdjusted OIBDA was $166 million versus $148 million in the prior-year quarterAdjusted EBITDA was $189 million versus $159 million in the prior-year quarterNEW YORK, Aug. 04, 2020 (GLOBE NEWSWIRE) — Warner Music Group Corp. today announced its third-quarter financial results for the period ended June 30, 2020.“We’re very pleased with our performance this quarter, especially in light of the global pandemic.  Our results highlight the underlying strength and resilience of our business.  Streaming revenue grew double digits and our digital transformation...

Continue reading

Strongbridge Biopharma plc Reports Second Quarter 2020 Financial Results and Provides Corporate Update

~ Reports KEVEYIS® (dichlorphenamide) Second Quarter 2020 Revenue of $7.8 Million, a 28 Percent Increase Compared to $6.1 Million During Second Quarter of 2019 ~~ Company Expects to Report Top-Line Results from the Phase 3 LOGICS Study of RECORLEV™ (levoketoconazole) in Endogenous Cushing’s Syndrome in September 2020 ~~ Increased Cash Position and Extended Runway to Fund Operations Through the First Quarter of 2022 Following Completion of a $30 Million Debt Facility ~~ Appointed John H. Johnson as Chief Executive Officer in July 2020 ~~ Strongbridge to Host Conference Call Today at 8:30 am ET ~DUBLIN, Ireland and TREVOSE, Pa., Aug. 04, 2020 (GLOBE NEWSWIRE) — Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases...

Continue reading

Medicenna Reports First Quarter Fiscal 2021 Financial Results and Operational Highlights

 – Further advances in recurrent glioblastoma program including submission of End of Phase 2 (“EOP2”) meeting package for MDNA55 – EOP2 meeting scheduled for 29th September, 2020 with FDA input expected in calendar Q4 2020  – Presented new preclinical data demonstrating the favorable safety profile and best-in-class potential of MDNA11 at ASCO 2020  – Depository Trust Certification (“DTC”) approved in July 2020TORONTO and HOUSTON, Aug. 04, 2020 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA; OTCQB: MDNAF), a clinical stage immuno-oncology company, today announced its financial results and operational highlights for the quarter ended June 30, 2020. All dollar amounts are expressed in Canadian currency unless otherwise noted.“I am very pleased...

Continue reading

Amerigo Announces Appointment of New Chief Financial Officer

VANCOUVER, British Columbia, Aug. 04, 2020 (GLOBE NEWSWIRE) — Amerigo Resources Ltd. (“Amerigo” or the “Company”) (TSX: ARG) is pleased to announce the appointment of Carmen Amezquita, CPA, CA as Chief Financial Officer, effective August 1, 2020.Carmen has served as the Chief Financial Officer and Corporate Controller for mining companies with both producing mines and exploration properties located in Latin America. Previous to that, she worked in the audit and assurance group at PricewaterhouseCoopers.Carmen is fluent in Spanish and received her Chartered Accountant designation in 2010. She holds a Bachelor of Arts degree from the University of British Columbia (“UBC”) and has a Diploma in Accounting from Sauder School of Business at UBC.About Amerigo and Minera Valle Central (“MVC”)Amerigo Resources Ltd....

Continue reading

Lupaka Secures Financing for Its Arbitration Claim Under The Canada-Peru Free Trade Agreement

VANCOUVER, British Columbia, Aug. 04, 2020 (GLOBE NEWSWIRE) — Lupaka Gold Corp. (“Lupaka Gold” or the “Company“) (TSX-V: LPK, FRA: LQP) reports that it has entered into an Arbitration Funding Agreement with Bench Walk Advisors (“BWA”) to support the Company’s arbitration claim against the Republic of Peru under the 2009 Canada-Peru Free Trade Agreement (“FTA”; see also the Company’s news release of 16 December 2019).The Agreement allows for up to USD$4.1 million to support the arbitration and related costs. All monies to be advanced by BWA are non-recourse and are only repayable upon completion of a successful claim where monies are recovered. As such, the financing is non-dilutive to current Lupaka shareholders. Precise terms of the Arbitration Funding Agreement (other than those set out herein) are confidential.The...

Continue reading

Mindleap Health™ Expands its Digital Mental Health Programs for Addiction, Psychedelic Integration and Holistic Wellness

DENVER, Aug. 04, 2020 (GLOBE NEWSWIRE) — Mydecine Innovations Group™ (CSE: MYCO) (OTC: NLBIF) (FSE:0NF) (“Mydecine”), is pleased to announce that its subsidiary, Mindleap Health™ (“Mindleap” or the “Company”) based in Vancouver, British Columbia, is expanding it’s digital therapeutic offerings by adding three additional programs to its platform.Mindleap™ is working towards contributing to the evolution of mental health and enabling the mass adoption of mental health treatments across the world. In order to expand access to world-class mental health solutions, Mindleap is developing new “30-day transformation” programs that will be offered as in-app purchases on the platform this fall.The new offerings will include comprehensive addiction, psychedelic integration, and holistic wellness programs designed to empower users...

Continue reading

ROBIT INITIATES EMPLOYEE COOPERATION NEGOTIATIONS IN FINLAND

ROBIT PLC        PRESS RELEASE        4 AUGUST 2020 AT 2.30 P.M.                     ROBIT INITIATES EMPLOYEE COOPERATION NEGOTIATIONS IN FINLANDRobit initiates employee cooperation negotiations in its subsidiary, Robit Finland Ltd, in relation to possible changes and actions to ensure and strengthen the company’s long-term profitability and cash flow. Robit disclosed the temporary lay-offs carried out in its Finnish units with a press release on 2 April 2020 as a part of preparing for COVID-19 situation.”In the present business environment, we are obliged to carry out also permanent cost savings based on profitability reasons, preparing at the same time for a longer duration of COVID-19 effects,” states Group CEO, Tommi Lehtonen.Employee cooperation negotiations cover senior salaried personnel of Robit Finland Ltd. Negotiations may result...

Continue reading

ROBIT KÄYNNISTÄÄ YT-NEUVOTTELUT SUOMESSA

ROBIT OYJ        LEHDISTÖTIEDOTE        4.8.2020 KLO 14.30ROBIT KÄYNNISTÄÄ YT-NEUVOTTELUT SUOMESSARobit käynnistää tytäryhtiössään, Robit Finland Oy:ssä yhteistoimintaneuvottelut mahdollisista muutoksista ja toimenpiteistä, joiden tarkoituksena on yrityksen kannattavuuden ja kassavirran varmistaminen ja vahvistaminen pitkällä aikavälillä. Robit ilmoitti Suomen yksiköissä toteutettavista lomautuksista lehdistötiedotteella 2.4.2020 johtuen varautumisesta COVID-19-tilanteeseen.”Nykyisessä toimintaympäristössä joudumme tekemään myös pysyviä kustannussäästöjä kannattavuussyistä varautuen samalla pidempään COVID-19-vaikutusaikaan,” toteaa toimitusjohtaja, Tommi Lehtonen.Neuvotteluiden kohteena ovat kaikki Robit Finland Oy:n ylempien toimihenkilöiden henkilöstöryhmään kuuluvat työntekijät. Neuvottelut voivat johtaa työvoiman pysyvään vähentämiseen...

Continue reading

Pacira BioSciences Announces FDA Acceptance of sNDA for EXPAREL Use in Pediatric Patients

sNDA submission based on positive Phase 3 data supporting expansion of the EXPAREL label to include use in children aged six and overPARSIPPANY, N.J., Aug. 04, 2020 (GLOBE NEWSWIRE) — Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced the U.S. Food and Drug Administration (FDA) has accepted the submission of its supplemental new drug application (sNDA) seeking expansion of the EXPAREL® (bupivacaine liposome injectable suspension) label to include single-dose infiltration to provide postsurgical analgesia in children aged six and over. The expected action date by the FDA under the Prescription Drug User Fee Act (PDUFA) is March 22, 2021.The sNDA is based on the positive data from the Phase 3 PLAY study of EXPAREL infiltration in pediatric patients undergoing spinal or cardiac surgeries. Overall findings were consistent with...

Continue reading

KemPharm to Report Second Quarter 2020 Financial Results

CELEBRATION, Fla., Aug. 04, 2020 (GLOBE NEWSWIRE) — KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the Company will host a conference call and live audio webcast on Wednesday, August 12, 2020, at 4:30 p.m. ET, to discuss its corporate and financial results for the second quarter 2020.Conference Call Information:(866) 395-2480 (U.S.)(678) 509-7538 (international)Conference ID: 5176398 An audio webcast with slide presentation will be accessible via the Investor Relations section of the Company’s website, http://investors.kempharm.com/. An archive of the webcast and presentation will be available for 90 days beginning at approximately 5:30 p.m. ET, on August 12, 2020.About KemPharm:KemPharm is a specialty pharmaceutical company...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.